NewsDesk @bactiman63 A scorpionfish protein could prove a powerful tool for treating multidrug-resistant bacterial infections in people with cystic fibrosis, shows a preliminary study published today...

Adaptive Phage Therapeutics, Inc., (APT) a clinical-stage biotechnology company advancing the APT phage bank, the world’s largest therapeutic phage initiative for treatment of bacterial infectious diseases,...

NewsDesk @bactiman63 Bacteriophages – viruses that kill bacteria–were successfully used for the first time to treat an antibiotic-resistant Mycobacterium abscessus  lung infection to allow a cystic...

NewsDesk @bactiman63 For the first time, researchers have successfully used bacteriophages – viruses that kill bacteria – to treat an antibiotic-resistant mycobacterial lung infection, clearing the...

Scientists from Johns Hopkins University and Medicine have developed a possible new antibiotic for a pathogen that is notoriously resistant to medications and frequently lethal for people with cystic fibrosis...

A new treatment developed by researchers at Aston University and Birmingham Children’s Hospital has been found to completely kill a bacterial infection that can be deadly to cystic fibrosis patients...

Clinical-stage specialty pharmaceutical company, Savara, Inc. today announced the initiation of the AVAIL study, a Phase III, randomized, double-blind, placebo-controlled study of AeroVanc (vancomycin...

The U.S. Food and Drug Administration today expanded the approved use of Kalydeco (ivacaftor) for treating cystic fibrosis. The approval triples the number of rare gene mutations that the drug can now...

Scientists from the University of Liverpool have shown that phage therapy could offer a safe and effective alternative to antibiotics in the treatment of Cystic Fibrosis lung infections. Chronic lung...

A powerful class of antibiotics provides life-saving relief for people with cystic fibrosis; however, a new study for the first time reveals the levels at which high cumulative dosages over time significantly...